PAVmed reports Q4 net income $1.3M; Lucid record tests, Veris financing, debt restructured

PAVmed Inc.

GAAP net income $1.3M ($0.12 diluted EPS); non-GAAP adjusted loss $0.7M ($0.06) per share.
Lucid processed 4,042 EsoGuard tests in Q4 (+84% YoY); secured first insurance coverage from Highmark Blue Cross Blue Shield.
Veris closed ~$2.4M private placement at $35M pre-money valuation to advance implantable monitor toward FDA clearance.
PAVmed cash $1.2M at Dec 31; pro forma $3.6M including Q1 2025 private placement.
Deconsolidation of Lucid and convertible debt restructuring added ~$25M to equity, regaining Nasdaq minimum equity compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.